Therefore, compared to cancers with lower sensitivity to PD-1 and PD-L1 inhibitors such as pancreatic cancer (98) and hepatocellular carcinoma (99), PD-1 inhibitor therapy for EC holds value in promoting TLS generation and maturation. The gene discussed is PDCD1; the disease is cancer.